Get ready for a major shakeup in the world of healthcare! Johnson & Johnson MedTech is undergoing a significant organizational transformation, and the implications are massive.
A New Era for J&J MedTech: Embracing Decentralization
In a bold move, J&J MedTech is saying goodbye to its regional model and embracing a business unit-led structure, effective January 1, 2026. This shift towards decentralization is a strategic decision aimed at streamlining operations and enhancing competitiveness.
The company's leadership, in an internal memo, highlighted the benefits of this change. They believe it will reduce bureaucracy, increase accountability, and enable faster decision-making. With a more specialized and connected approach, J&J MedTech aims to deliver better outcomes for patients and healthcare providers worldwide.
But here's where it gets controversial...
The Separation of DePuy Synthes Orthopaedics
Coinciding with this restructuring is J&J's decision to separate its DePuy Synthes Orthopaedics business. This move, announced last month, is designed to enhance strategic focus and drive stakeholder value. However, it also raises questions about the future of J&J MedTech's orthopedic division, which represents a significant portion of its global business.
A Johnson & Johnson spokesperson emphasized their commitment to improving lives and strengthening their organizational structure. They believe this change will create a simpler, faster, and more competitive entity, better serving patients and customers.
The Impact on Business Units
The initial transition to business units has already brought about positive changes, according to the J&J MedTech memo. It simplified workflows, clarified accountability, and accelerated decision-making, allowing teams to understand their contributions to business success more clearly.
Now, with the planned separation of Orthopaedics, J&J MedTech is reevaluating its approach across Cardiovascular, Surgery, and Vision units. This restructuring is a response to the evolving medtech industry, aiming for deeper specialization and faster, more connected ways of working within each business unit.
From January 1, 2026, each unit will have full responsibility for its global business performance, from strategy to execution. All commercial leadership will report directly to the business units, further emphasizing the decentralized approach.
Regional Leadership and Supply Chain Updates
Surgery and Electrophysiology will establish distinct regional leadership structures, with Surgery reporting to Hani Abouhalka and EP to Michael Bodner. The regional Supply Chain teams will now report to MedTech Supply Chain under Luis Roman. Enterprise Functions are also expected to realign their structures to support the new operating model.
However, this shift does not impact customer-facing roles, the U.S. commercial structure, or the Vision, Heart Recovery, and Circulatory Restoration units, which already operate under this model. China's operations will remain unchanged.
Leadership Changes and Regional Focus
With this decision, J&J MedTech is moving away from cross-MedTech leadership teams in regions and markets. Gustavo Gala, VP of MedTech LATAM, will oversee the implementation of these changes. Vishnu Kalra, the new international president of DePuy Synthes, will report to Namal Nawana, and Orthopaedics market and cluster leaders across all OUS regions will shift to report to Kalra in 2026. Gavin Wood, company group chair of MedTech EMEA, will support the transition until mid-2026.
This restructuring is a significant step for J&J MedTech, and it will be interesting to see how it impacts the company's future success.
And this is the part most people miss...
What do you think about J&J MedTech's new business unit-led structure? Do you believe it will enhance their competitiveness and improve patient care? Share your thoughts in the comments below! We'd love to hear your insights and opinions on this major healthcare industry shift.
